OUR PATENTS

INSULIN MANAGEMENT

This internet posting serves as notice under 35 U.S.C. §287(a) that the following Insulet products may be covered by the following U.S. patent(s). Each product may also be covered by one or more foreign patents, and additional patent application(s) may be pending.

Omnipod® Insulin Management System

  • 10,438,698 (Omnipod DASH® System)
  • 10,420,883 (Omnipod System and Omnipod DASH System)
  • 9,402,950 (Omnipod System and Omnipod DASH System)
  • 7,771,412 (Omnipod System and Omnipod DASH System)
  • 7,303,549 (Omnipod System and Omnipod DASH System)
  • 7,137,964 (Omnipod System and Omnipod DASH System)
  • 7,029,455 (Omnipod System and Omnipod DASH System)
  • 6,740,059 (Omnipod System and Omnipod DASH System)
  • D874,471 (Omnipod DASH System)
  • D872,734 (Omnipod DASH System)
  • D872,733 (Omnipod DASH System)
  • D869,495 (Omnipod DASH System)
  • D869,479 (Omnipod DASH System)
  • D862,500 (Omnipod DASH System)
  • D851,658 (Omnipod DASH System)
  • D839,284 (Omnipod DASH System)
  • D838,731 (Omnipod DASH System)
  • D836,123 (Omnipod DASH System)
  • D826,957 (Omnipod DASH System)
  • D826,956 (Omnipod DASH System)

Omnipod® Delivery Systems

  • 10,420,883
  • 9,402,950
  • 7,771,412
  • 7,303,549
  • 7,137,964
  • 7,029,455
  • 6,740,059

ABOUT INSULET CORPORATION:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod® product platform. The Omnipod® Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnipod® technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 100,000 users across the globe rely on Insulet's Omnipod® Insulin Management System to bring simplicity and freedom to their lives.

Starting July 1, 2018, Insulet will assume direct distribution of its Omnipod® Insulin Management System in Europe, including sales, marketing, training and customer support activities. This will allow Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long-term, as it already does in the United States and Canada. European customers can find additional information about our transition at www.omnipodeurope.com and can also register for email updates. For information about the current distribution of the Omnipod® Insulin Management System in Europe and support before July 1, 2018, please visit www.mylife-diabetescare.com/mylife-omnipod-product-overview.html.